Abstract | BACKGROUND AND PURPOSE: The K(Ca) 3.1 channel is a potential target for therapy of immune disease. We identified a compound from a new chemical class of K(Ca) 3.1 inhibitors and assessed in vitro and in vivo inhibition of immune responses. EXPERIMENTAL APPROACH: We characterized the benzothiazinone NS6180 (4-[[3-(trifluoromethyl)phenyl]methyl]-2H-1,4-benzothiazin-3(4H)-one) with respect to potency and molecular site of action on K(Ca) 3.1 channels, selectivity towards other targets, effects on T-cell activation as well as pharmacokinetics and inflammation control in colitis induced by 2,4-dinitrobenzene sulfonic acid, a rat model of inflammatory bowel disease (IBD). KEY RESULTS:
NS6180 inhibited cloned human K(Ca) 3.1 channels (IC(50) = 9 nM) via T250 and V275, the same amino acid residues conferring sensitivity to triarylmethanes such as like TRAM-34. NS6180 inhibited endogenously expressed K(Ca) 3.1 channels in human, mouse and rat erythrocytes, with similar potencies (15-20 nM). NS6180 suppressed rat and mouse splenocyte proliferation at submicrolar concentrations and potently inhibited IL-2 and IFN-γ production, while exerting smaller effects on IL-4 and TNF-α and no effect on IL-17 production. Antibody staining showed K(Ca) 3.1 channels in healthy colon and strong up-regulation in association with infiltrating immune cells after induction of colitis. Despite poor plasma exposure, NS6180 (3 and 10 mg·kg(-1) b.i.d.) dampened colon inflammation and improved body weight gain as effectively as the standard IBD drug sulfasalazine (300 mg·kg(-1) q.d.). CONCLUSIONS AND IMPLICATIONS:
NS6180 represents a novel class of K(Ca) 3.1 channel inhibitors which inhibited experimental colitis, suggesting K(Ca) 3.1 channels as targets for pharmacological control of intestinal inflammation.
|
Authors | D Strøbæk, D T Brown, D P Jenkins, Y-J Chen, N Coleman, Y Ando, P Chiu, S Jørgensen, J Demnitz, H Wulff, P Christophersen |
Journal | British journal of pharmacology
(Br J Pharmacol)
Vol. 168
Issue 2
Pg. 432-44
(Jan 2013)
ISSN: 1476-5381 [Electronic] England |
PMID | 22891655
(Publication Type: Journal Article)
|
Copyright | © 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society. |
Chemical References |
- 4-((3-(trifluoromethyl)phenyl)methyl)-2H-1,4-benzothiazin-3(4H)-one
- Intermediate-Conductance Calcium-Activated Potassium Channels
- Kcnn4 protein, mouse
- Potassium Channel Blockers
- Thiazines
- 2,4-dinitrofluorobenzene sulfonic acid
- Dinitrofluorobenzene
|
Topics |
- Animals
- Dinitrofluorobenzene
(analogs & derivatives)
- Disease Models, Animal
- Erythrocytes
(drug effects, physiology)
- Humans
- Inflammation
(drug therapy)
- Inflammatory Bowel Diseases
(drug therapy, immunology)
- Intermediate-Conductance Calcium-Activated Potassium Channels
(physiology)
- Lymphocyte Activation
(drug effects)
- Male
- Mice
- Mice, Knockout
- Potassium Channel Blockers
(blood, pharmacology, therapeutic use)
- Rats
- Rats, Wistar
- T-Lymphocytes
(drug effects, immunology)
- Thiazines
(blood, pharmacology, therapeutic use)
|